Stock Track | Bioventus Surges 6.71% Pre-Market on Strong Q3 Results and Reaffirmed Guidance

Stock Track

Nov 04, 2025

Bioventus Inc. (BVS) shares soared 6.71% in pre-market trading on Tuesday following the release of its strong third-quarter financial results. The company reported Q3 revenue of $138.7 million, surpassing analyst expectations of $138.2 million, while adjusted earnings per share came in at $0.15, beating the consensus estimate of $0.12.

The medical device company demonstrated robust organic revenue growth of 8.2% year-over-year, driven by above-market growth across all three areas of its portfolio. Bioventus President and CEO Rob Claypoole highlighted the exceptional quarter, noting "momentum continued to build across our portfolio as our team delivered above-market organic revenue growth, increased profitability, and significant cash flow acceleration."

Adding to investor optimism, Bioventus reaffirmed its full-year 2025 financial guidance. The company expects net sales between $560 million and $570 million, representing organic growth of approximately 6.1% to 8.0%. Adjusted EBITDA is projected to be in the range of $112 million to $116 million, with non-GAAP EPS forecasted between $0.64 and $0.68.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1180775765"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180775765\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180775765?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180775765","market":"sg","top_or_hot":-1,"title":"Stock Track | Bioventus Surges 6.71% Pre-Market on Strong Q3 Results and Reaffirmed Guidance","media":"Stock Track","content":"<p>Bioventus Inc. (BVS) shares soared 6.71% in pre-market trading on Tuesday following the release of its strong third-quarter financial results. The company reported Q3 revenue of $138.7 million, surpassing analyst expectations of $138.2 million, while adjusted earnings per share came in at $0.15, beating the consensus estimate of $0.12.</p>\n\n<p>The medical device company demonstrated robust organic revenue growth of 8.2% year-over-year, driven by above-market growth across all three areas of its portfolio. Bioventus President and CEO Rob Claypoole highlighted the exceptional quarter, noting \"momentum continued to build across our portfolio as our team delivered above-market organic revenue growth, increased profitability, and significant cash flow acceleration.\"</p>\n\n<p>Adding to investor optimism, Bioventus reaffirmed its full-year 2025 financial guidance. The company expects net sales between $560 million and $570 million, representing organic growth of approximately 6.1% to 8.0%. Adjusted EBITDA is projected to be in the range of $112 million to $116 million, with non-GAAP EPS forecasted between $0.64 and $0.68.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bioventus Surges 6.71% Pre-Market on Strong Q3 Results and Reaffirmed Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bioventus Surges 6.71% Pre-Market on Strong Q3 Results and Reaffirmed Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bioventus Inc. (BVS) shares soared 6.71% in pre-market trading on Tuesday following the release of its strong third-quarter financial results. The company reported Q3 revenue of $138.7 million, surpassing analyst expectations of $138.2 million, while adjusted earnings per share came in at $0.15, beating the consensus estimate of $0.12.</p>\n\n<p>The medical device company demonstrated robust organic revenue growth of 8.2% year-over-year, driven by above-market growth across all three areas of its portfolio. Bioventus President and CEO Rob Claypoole highlighted the exceptional quarter, noting \"momentum continued to build across our portfolio as our team delivered above-market organic revenue growth, increased profitability, and significant cash flow acceleration.\"</p>\n\n<p>Adding to investor optimism, Bioventus reaffirmed its full-year 2025 financial guidance. The company expects net sales between $560 million and $570 million, representing organic growth of approximately 6.1% to 8.0%. Adjusted EBITDA is projected to be in the range of $112 million to $116 million, with non-GAAP EPS forecasted between $0.64 and $0.68.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BVS","symbol_name":"Bioventus Inc.","start_time":0,"source_url":"","article_id":"1180775765","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180775765","pubTimestamp":1762261703,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Bioventus Inc. (BVS) shares soared 6.71% in pre-market trading on Tuesday following the release of its strong third-quarter financial results. The company reported Q3 revenue of $138.7 million,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BVS":"Bioventus Inc."},"translate_title":"个股追踪|Bioventus盘前大涨6.71%，Q3业绩强劲，指引重申","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BVS":1},"content_text":"Bioventus Inc. (BVS) shares soared 6.71% in pre-market trading on Tuesday following the release of its strong third-quarter financial results. The company reported Q3 revenue of $138.7 million, surpassing analyst expectations of $138.2 million, while adjusted earnings per share came in at $0.15, beating the consensus estimate of $0.12.\nThe medical device company demonstrated robust organic revenue growth of 8.2% year-over-year, driven by above-market growth across all three areas of its portfolio. Bioventus President and CEO Rob Claypoole highlighted the exceptional quarter, noting \"momentum continued to build across our portfolio as our team delivered above-market organic revenue growth, increased profitability, and significant cash flow acceleration.\"\nAdding to investor optimism, Bioventus reaffirmed its full-year 2025 financial guidance. The company expects net sales between $560 million and $570 million, representing organic growth of approximately 6.1% to 8.0%. Adjusted EBITDA is projected to be in the range of $112 million to $116 million, with non-GAAP EPS forecasted between $0.64 and $0.68.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}